Drugs / MVSTr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02231853 | Sep 2014 → Nov 2017 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVSTr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02231853 ↗ |
| Modality | Cell therapy | “GMP-grade allogeneic MVSTr from the stem cell donor will be generated using or peripheral blood mononuclear cells (PBMCs) pulsed with overlapping peptide libraries of...” NCT02231853 ↗ |
| Route | Other | “1x10e6 MVSTr/kg infusion” NCT02231853 ↗ |